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ABSTRACT 
Postdural puncture headache (PDPH) is a relatively common complication of neuraxial 
anesthesia, with an occurrence rate as high as 50% following inadvertent dural puncture (Kwak, 
2017). Due to the disabling nature of these headaches, interventions are focused at bringing relief 
to those suffering from this complication. While epidural blood patches are highly effective at 
treating PDPH and are considered the gold standard, they are not risk-free. A less-invasive 
alternative to the epidural blood patch is emerging as an effective intervention for treating 
PDPH. There is now growing evidence and emerging consensus opinion among anesthesia 
experts that SPGNBs are useful as a treatment of PDPH before attempting the epidural blood 
patch. The purpose of this Doctor of Nursing Practice (DNP) project is to modify a current 
nationally published clinical practice guideline (CPG) for the treatment of PDPH to include the 
early consideration for SPGNB and to further adapt the CPG for local implementation. The 
question this project addressed is whether the modified CPG would be appraised, using the 
Appraisal of Guidelines for Research and Evaluation II (AGREE II) to be of higher quality than 
the original CPG. The theoretical framework guiding this project was Lewin’s Change Theory. 
The modified CPG was presented to stakeholders at a local healthcare facility in metro Phoenix, 
Arizona for consideration of implementation. This DNP quality improvement project intended to 
translate emerging evidence into a local practice for the benefit of improving consistency of 
evidence-based care. 
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INTRODUCTION 
Epidural and spinal anesthesia are modern, common neuraxial techniques used to provide 
safe and effective pain relief during surgical and diagnostic procedures. These neuraxial 
techniques are not risk-free. While the complication rate from neuraxial anesthesia is generally 
low, complications can cause serious repercussions. One of the most common complications of 
neuraxial anesthesia is that of a postdural puncture headache (Nguyen & Walters, 2014). These 
headaches result from a small tear in the dural membrane of the spinal column, allowing cerebral 
spinal fluid (CSF) to leak into the epidural space. The exact mechanism for these headaches is 
still debated in the literature; however, it is commonly believed to be related to an increased 
pressure gradient between atmospheric pressure and reduced CSF pressure resulting from the 
leak (Cohen et al., 2014). Some researchers suspect the mechanism to be related to cerebral 
vasodilation as a compensatory mechanism to the drop in CSF pressure (Bezov, Ashina, & 
Lipton, 2010). 
Kwak (2017) reports that 1.5% of patients receiving an epidural will experience a dural 
tear and, of those, approximately 50% will go on to develop a postdural puncture headache 
(PDPH). These headaches are often mild and resolve within 24 hours without intervention, 
however, on occasion they can become quite severe and disabling, requiring medical 
intervention. PDPHs have been described in the literature as severe frontal or occipital 
headaches, postural in nature (worse sitting & standing) and often disabling in severity (Nguyen 
& Walters, 2014). PDPHs can be accompanied by visual and auditory disturbances, nausea, 
vomiting, and vertigo (Nguyen & Walters, 2014). The pain can be so disabling that patients 
become bed-ridden or they seek help from a hospital emergency room. 
   
11 
Nguyen and Walters (2014) reported that the onset of PDPH is typically within the first 
three days following a dural puncture (90%) and many (60%) develop PDPH within two days 
following a dural puncture. Cohen et al. (2014), reported that 40% of patients present with PDPH 
within “several hours” following a dural puncture. It is also known that approximately 47% of 
PDPH cases will self-resolve without medical management within four days and 85% of PDPH 
cases will resolve within six weeks (Bezov et al., 2010). Due to the severity and disabling nature 
of these PDPHs, the focus remains on interventions that will bring relief to those suffering from 
this complication. 
Background Knowledge 
Traditional treatments for PDPH are widely discussed in the literature and include 
interventions such as bed rest, intravenous (IV) fluids, IV caffeine, aminophylline, gabapentin, 
multiple other pharmacological agents, and epidural blood patch. Except for epidural blood 
patch, the generally accepted gold-standard of PDPH care, there is little consensus for other 
treatment modalities. Many of the current interventions and practices utilized by anesthesia 
providers lack the support by randomized, rigorous research-based studies (Nguyen & Walters, 
2014). To compound the problem, in a broad survey of anesthesia providers in North America 
conducted in 2008 regarding the standard of care for PDPH, only 14% of practitioners reported 
following a standardized protocol or clinical practice guideline (CPG) for the treatment of PDPH 
(Baysinger, Pope, Lockhart, & Mercaldo, 2011). 
The epidural blood patch, while considered the gold-standard with documented 
effectiveness ranging from 61% to 98% for patients with PDPH, is an invasive procedure 
requiring a skilled clinician (Cohen et al., 2014). Additionally, the epidural blood patch is 
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associated with numerous complications, including subdural and epidural hematoma, a 
secondary dural tear with the potential to exacerbate the original PDPH, increased back pain, and 
risk for infection within the central nervous system (Cohen et al., 2014). 
A less-known and less invasive alternative to the epidural blood patch is emerging as an 
effective approach for treating PDPH are sphenopalatine ganglion nerve blocks (Kent & 
Mehaffey, 2016). Sphenopalatine ganglion nerve blocks (SPGNBs) are not new to medicine; 
they have been used effectively for over 100 years for the treatment of various other forms of a 
headache, neuralgias and even temporomandibular joint pain (Fulkerson, 2017). 
The sphenopalatine ganglion is located immediately posterior to the middle turbinates in 
an area called the pterygopalatine fossa (Robbins et al., 2015). It is the most extensive collection 
of neurons within the peripheral nervous system and is composed primarily of parasympathetic 
fibers but also contains some sympathetic and sensory fibers as well (Robbins et al., 2015). The 
parasympathetic fibers from this ganglion innervate the cerebral and meningeal blood vessels. 
When the volume or pressure of cerebral spinal fluid is reduced, as can occur with a dural 
puncture, parasympathetic nerves reflexively stimulate the cerebral meningeal vessels to dilate in 
compensation (Robbins et al., 2015). Gharaei and Nabi (2015) describe three possible 
mechanisms for how SPGNBs may mitigate the symptoms of PDPH. These include: 
1. Interruption of the post-ganglionic parasympathetic path, inhibiting nociception and 
blocking cephalic autonomic symptoms; 
2. Modulation of the sensory process within the trigeminal nucleus; and 
3. Interruption of postganglionic sympathetic outflow via neural blockade of 
sympathetic fibers. 
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While large randomized controlled clinical trials do not yet support the use of SPGNBs 
for the treatment of PDPHs, there is emerging and growing evidence from smaller cohort studies, 
case reports, study abstracts, and anecdotal experiences from numerous clinicians regarding 
SPGNB effectiveness (Fulkerson, 2017). Considering the ease of performing an SPGNB and the 
low-risk and non-invasive nature of this procedure, it is intuitive to consider this procedure 
before the more invasive and higher-risk epidural blood patch. When clinicians exclusively 
consider best practices that are exclusively backed by multiple, large, well-designed, double-
blind, randomized control trials, they may overlook appropriate practices and interventions that 
are still supported, be it with smaller, less statistically powerful studies (Higgs, Burn, & Jones, 
2001). The wealth of knowledge supporting best practices not only derives from formal research, 
but also that gained from individual clinical practice knowledge, scientific reasoning, and 
judgments based on professional experiences (Higgs et al., 2001). These authors’ insight is 
applicable with the suggestion that PDPH treatment should include the early consideration for 
SPGNB. 
Local Problem 
A local healthcare facility in metro Phoenix, Arizona (“the local facility”) was a primary 
anesthesia practice site for Anesthesia Physicians of Arizona (APA). The APA provided the local 
facility approximately 32 certified registered nurse anesthetists (CRNAs) and physician 
anesthesiologists (MDAs). Similar to the national data published by Baysinger et al. (2011), and 
from observations and conversations with anesthesia providers who practice at the local facility, 
variations to treatment approaches for PDPH were discovered. It appeared there were some 
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differences among anesthesia providers as to whether SPGNB was even considered or attempted 
before an epidural blood patch for the treatment of PDPH. 
Purpose of the Project 
The purpose of this DNP project was to modify an existing, and well respected, clinical 
practice guideline (CPG) published by the New York School of Regional Anesthesia (NYSORA) 
for the treatment of postdural puncture headaches (Appendix A) to include the early 
consideration of SPGNB (Harrington & Reina, 2019). This modified NYSORA CPG (Appendix 
B) was presented for review and consideration amongst key APA stakeholders practicing at the 
local facility. The APA’s anesthesia providers at the local facility lacked a formal written, locally 
adopted clinical practice guideline for the treatment of PDPH at the local facility. This modified 
CPG potentially provided patients suffering from PDPH the less-invasive SPGNB alternative 
before attempting an epidural blood patch. The project aimed to introduce the SPGNB as an 
early intervention consideration for the treatment of PDPH, before more invasive and higher risk 
interventions are attempted. A clinical practice guideline for the treatment of PDPH was 
modified and disseminated to the key APA’s anesthesia stakeholders practicing at the local 
facility, providing a step-wise, best-practices approach for treating this disabling condition. 
Project Question 
This DNP project was based on the following question: Would local stakeholders, using 
the AGREE II tool, score evidence supporting the recommendation of including SPGNB for the 
treatment of PDPH as equal or of higher quality than the existing or current modalities of 
treatment as provided by the NYSORA CPG for the treatment of PDPH? 
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THEORETICAL FRAMEWORK 
Eccles, Foy, Sales, Wensing, and Mittman (2012) estimate that up to 40% of patient care 
in the United States does not reflect the latest evidence-based practices and up to 25% of patients 
receive care that has not been proven to be effective. It has been well documented that it takes as 
long as 17 years from when knowledge is gained from research to the time it is implemented into 
practice as a standard of care (Morris, Wooding, & Grant, 2011). Healthcare practitioners are 
under increasing pressure to deliver evidence-based patient care while at the same time being 
burdened with increased expectations for documentation, meeting compliance regulations, and 
addressing insurance demands for proper coding (Grimshaw, Eccles, Lavis, Hill, & Squires, 
2012). There is also an ever-increasing demand for healthcare providers to improve efficiencies 
in their clinical practice; delivering better, evidence-based care that improves outcomes to more 
patients in a tighter timeframe. 
Changing clinical practice requires a systematic, thoughtful approach; one that provides 
clinical leadership with the tools to strategically navigate through the maze of social psychology 
and overcome political power structures found within every organization. Introducing new 
clinical change into practice mandates a departure from the status quo; disruption to the daily 
routines that provide a haven of comfort to practitioners. The change theory, as developed and 
taught by Kurt Lewin (Mitchell, 2013) provides the theoretical framework for this DNP project 
and guiding principles for development and introduction of a new clinical practice guideline for 
the treatment of PDPH (Figure 1). Kurt Lewin understood human psychology, sociology, and the 
forces which must be overcome to motivate individuals and groups to give up their comfortable 
routines for something that is new and unfamiliar (Mitchell, 2013). The three fundamental 
   
16 
elements of the change theory include: unfreezing, moving and refreezing (Burnes, 2004). From 
an administrative perspective, this DNP project required the formation of a committee who 
served as counselors to help guide the project to completion using a systematic, team-based 
approach. Additionally, professional industry consultants from the local site were selected and 
involved in providing expert opinion and organizational insight as to how this DNP project 
would best suit the local stakeholder needs. 
 
FIGURE 1. Adaptation of Lewin’s change theory. 
Change Theory – Unfreezing 
It is human nature to resist change and cling to familiar practices (Burnes & Bargal, 
2017). With a keen understanding of this human predisposition, Lewin proposed that change can 
only occur when: 1) the status quo becomes increasingly uncomfortable, and 2) it requires more 
energy to remain in the status quo than what would be required to change (Burnes & Bargal, 
2017). Clinicians may be aware that a portion of their practice does not reflect evidence-based 
best practices. However, they become comfortable in their daily practice and are unwilling to 
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exert the energy needed to adopt new methods. Lewin suggested that the purposeful introduction 
of ‘controlled chaos' into a system, generating unease and discomfort as a catalyst for change 
was necessary for change to occur (Burnes & Bargal, 2017). In the absence of having an 
institutionalized CPG to follow when treating PDPH, clinicians are left to follow their best 
judgment, relying on formal and informal training, personal clinical experiences, vaguely defined 
treatment practices, and perhaps the need to search the literature for best practices. The creation 
of an institutionalized clinical practice guideline for the treatment of PDPH provides a 
standardized path and one that reflects the newest and latest research and evidence-based 
practices. 
Problem Identification 
Identification of a potential gap in care was at the heart of this DNP project. The problem 
identified within the DNP project addressed the then current treatment regime for PDPHs 
following neuraxial anesthesia and the frequent failure to consider using an SPGNB as a 
potential and viable treatment option before attempting more aggressive and invasive techniques. 
Unfreezing the present situation begins with the identification of a problem; targeting a clinical 
need and reason for the change. Current practices for the treatment of PDPH include a vast array 
of interventions, some proven to be effective, however many others are not yet strongly 
supported by the literature. Baysinger, Pope, Lockhart, and Mercaldo (2011), in their 2008 
nationwide survey of 843 anesthesia practitioners regarding current treatment preferences for 
PDPH, found that: 1) standardized protocols for treatment of PDPH are uncommon and often not 
followed, and 2) current practices include everything from conservative measures (bed rest, oral 
hydration, IV fluids, caffeine, NSAIDs, & opioids) to the more aggressive intervention of an 
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epidural blood patch. The literature reflects other treatment modalities for PDPH that would 
require the unfreezing of current clinical practices, including the use of abdominal binders, IV 
aminophylline, dexamethasone and epidural morphine (Bezov et al., 2010). 
Goals and Priorities 
Establishing goals and priorities are critical to charting a way forward and providing a 
purpose for unfreezing the current state. Due to a wide variety of current practices for the 
treatment of PDPH and a lack of well-defined, evidence-based protocols, a need was established 
to provide local anesthesia practitioners with a clinical practice guideline. This CPG incorporated 
the best practices for the treatment of PDPH and introduced a promising, effective and less-
invasive intervention, such as the SPGNB. Therefore, the goal of this DNP project was to modify 
and introduce a locally implementable CPG for the treatment of PDPH which would include the 
use of SPGNB. The CPG was modified following an extensive literature review and with input 
from industry expert advisors. The modification was necessary for local and institutional 
feasibility and recommendation for local implementation once it was determined to be valid, 
appropriate, and easy to follow, as determined by the AGREE II scoring instrument (Appendix 
C) (Brouwers et al., 2010). Stakeholder feedback was obtained following the presentation of the 
modified CPG to determine better their perceptions of the guidelines and willingness to adopt 
them into local clinical practice. 
Change Theory – Moving 
Lewin’s moving step involves behavioral modification; departing from the status quo into 
new, seemingly uncharted and often uncomfortable territory. Key to the success of this critical 
step is that of strong, transformational leadership (Marshall & Broome, 2016). Vital to the 
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successful implementation of this CPG amongst APA anesthesia providers practicing at the local 
facility were the formal leaders and stakeholders that embraced the concept, as well as the strong 
involvement of multiple informal anesthesia providers who lacked the formal institutional 
positional authority, yet they had tremendous informal influence throughout the ranks of their 
peer colleagues. Local social networking channels and peer-to-peer influences were considered 
for this CPG implementation to be ultimately successful. 
Team Formation 
This DNP project embraced a team concept, both regarding this project’s academic 
advisement committee and the inclusion of on-site APA anesthesia experts practicing at the local 
facility who assisted in the review and assessment of the proposed revised CPG and evaluated 
the applicability of it for local implementation. The APA’s anesthesia consultants provided 
practice and institutional insight, which was instrumental to the unfreezing, moving and re-
freezing steps leading to final clinical team acceptance of this CPG at their institution. 
Review, Critique and Synthesis of Literature 
Literature synthesis provided input that reflected the most relevant, valid and applicable 
evidence for the inclusion of SPGNBs within the clinical practice guideline for treating PDPH. 
Current practices for the treatment of PDPH, as described in the NYSORA CPG, were assessed 
and scored using the AGREE II instrument and a modified CPG with the inclusion of SPGNB 
was then developed and introduced, focusing the anesthesia clinicians at the local facility on a set 
of treatment guidelines that reflect best practices and current evidence. 
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Evaluation and Analysis 
It was not the specific scope of this DNP project to fully implement a new or revised 
CPG at a local institution because this project author neither had the authority nor positional 
standing as a student in a clinical rotation to do so. However, the project did endeavor to present 
and disseminate relevant data and CPG recommendations to the APA’s anesthesia stakeholders 
practicing at the local facility for their consideration of implementation, based upon the input and 
feedback from their expert consultations. In this regard, the data, tools, and modified CPG were 
provided to the anesthesia team stakeholders for their review. The NYSORA CPG that was 
modified as part of this DNP project was evaluated via the AGREE II assessment tool by two 
trained local anesthesia experts from the local facility. After the AGREE II scoring of the 
modified CPG, APA anesthesia stakeholder feedback was collected and evaluated, addressing 
their feedback of the modified CPG regarding local applicability for implementation at the local 
facility. 
Change Theory – Refreezing 
Permanent, lasting change is sustainable when new ideas, values, and clinical practices 
are fully embraced, become comfortable once again, and the emotional energy required to return 
to old practices is maintained higher than the energy level required to continue forward with the 
newly-acquired practices (Burnes, 2004). Vital to the success of this sustained effort was the 
early incorporation of the local facility’s anesthesia stakeholder team, assuring the modified CPG 
for treatment of PHPH aligned well with their institutional needs and assured the treatment 
recommendations for PDPH reflected their professional clinical judgments for best practices. 
The use of both the AGREE II CPG assessment tool and the incorporation of input from local 
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anesthesia expert consultation (Appendix D & E) increased the likelihood for permanent, lasting 
change which embraces best-practices, as reflected in the modified CPG for PDPH that was 
presented. 
Concepts and Terms 
This DNP project addresses several significant concepts and terms, including postdural 
puncture headache (PDPH), sphenopalatine ganglion nerve block (SPGNB), clinical practice 
guidelines (CPG), and evidence-based practice (EBP). 
Postdural puncture headache (PDPH) is defined as a headache that develops within a 
five-day timeframe following dural puncture that cannot be identified as having a more obvious 
etiology than the dural puncture itself (The International Classification of Headache Disorders, 
2013). These headaches can range from mild to severe, most frequently exhibit a postural 
element and can be accompanied by visual and auditory disturbances, nausea, vomiting and a 
stiff neck (Nguyen & Walters, 2014). Some 40% develop with a few hours following a dural 
puncture and up to 90% present within three days (Nguyen & Walters, 2014).  
Sphenopalatine ganglion nerve block (SPGNB) is defined in the literature as a block of 
the sphenopalatine ganglion using either topical local anesthetic, an injection of local anesthetic 
or ablation of the sphenopalatine ganglion (Puledda & Goadsby, 2016). For this DNP project, the 
SPG block is defined as a block of the sphenopalatine ganglion using a topical local anesthetic 
application using a trans-nasal approach with a cotton swab applicator or similar device. 
Clinical practice guidelines (CPG) is defined as a recommended treatment standard, 
informed by a systematic review of the literature, that help guide a clinician, when combined 
with clinical experience and critical thinking, in developing a treatment plan which optimizes 
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patient outcomes (Murad, 2017). Clinical practice guidelines serve as sound, standardized 
clinical application of knowledge and evidence supported in the literature. 
Evidence-based practice (EBP) is defined as the application of evidence-based research, 
modified through critical thinking, clinical experience and professional expertise adapted to local 
practice and needs in providing personalized patient care that represents the best and currently 
available information (Higgs, Burn, & Jones, 2001). It is argued by Higgs et al. (2001) that 
evidence-based practice not only includes qualitative and quantitative research data from large, 
well-designed randomized control trials but also, and importantly, should include knowledge 
gained from smaller observational cohort studies and case reports, combined with professional 
clinical experiences and application of expert critical reasoning. 
REVIEW OF LITERATURE 
Literature Search 
Relevant validated and current research, both qualitative and quantitative, found in the 
peer-reviewed literature are at the heart of any honest inquiry regarding best practices (Jones, 
Stewart, Darer, & Sittig, 2013). Additionally, clinicians must also consider personal practice 
experiences and clinical reasoning when deciding how and when to modify their practices to 
reflect the best evidence (Higgs et al., 2001). This DNP project sought to answer a question 
regarding the modification of a clinical practice guideline for treating PDPH and whether local 
stakeholders at the local facility would consider the modified CPG to be evidence-based and 
applicable to their institution. In pursuit of answers to these questions, an existing NYSORA 
CPG (Appendix A) was updated and modified, including the early employment of an SPGNB, 
when appropriate, and a presentation to anesthesia stakeholders at the local facility was made 
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regarding the modifications and rationale for inclusion of SPGNB for the treatment of PDPH. To 
this effort, a literature search and synthesis of evidence was required to evaluate the support for 
the inclusion of SPG blocks for the treatment of PDPH. 
Search Terms 
Commonly accepted scientific literature search engines were used to query terms and 
phrases of interest. The CINAHL, Ovid, PubMed, Google Scholar, and clinicaltrials.gov 
databases were searched using keywords and phrases, including: “sphenopalatine ganglion” OR 
“SPG” OR “pterygopalatine ganglion” OR “Meckel's ganglion” AND “postdural puncture” OR 
“postdural puncture” OR “a headache.” Additionally, a search was conducted using: “clinical 
practice guidelines” OR “CPG” OR “treatment recommendations” OR “treatment guidelines” 
AND “postdural puncture headache” OR “postdural puncture headache” OR “PDPH.” 
Search Criteria 
Initially, no date, language or other filters were applied to aid in determining the breadth of 
available literature, in general. Titles and abstracts were reviewed to assess the relevance and for 
sorting duplications. Subsequent searches were conducted using restricted date ranges; however, 
due to the limited number of studies and data available, all filters were removed again for the 
inclusion of several reports and studies that would have otherwise been eliminated. It is 
recognized by this DNP project author that generally, only recent and relevant literature should 
be included, however, when there was a lack of recent literature and older literature still remains 
valid and supports current practices, it was included for review and analysis within this project. 
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Exclusion Criteria 
Only original research studies, abstracts, and reports were selected, eliminating all other 
duplicate or editorial articles that were not directly reporting original study data or observations. 
Review of Literature Findings 
Of the 17 case-reports, case series, abstracts, and retrospective observational studies 
found on the topic, 11 were selected and included herein for further analysis and discussion 
(Table 1). While the number of studies, abstracts and reports were limited, all were supportive of 
SPGNBs, and no literature was found that did not, in some way, support the practice of SPGNB. 
Six studies or reports were ultimately eliminated due to either duplication of data or dates that 
were more than 10 years old with no additional value to newer information found within the 
literature. 
Strengths 
Sphenopalatine ganglion nerve blocks (SPGNBs) have a well-established and successful 
history spanning back as far as 1908 in treating various headache-related and neuropathic pain 
conditions (Waldman, 1993). There have been numerous case reports, published abstracts, peer-
reviewed articles, and professional conference presentations on the topic of SPGNBs. Not only 
does the anesthesia literature support this procedure, but it is also well discussed within 
emergency medicine, headache and pain management journals, and at conferences worldwide. 
While many industry experts have acknowledged that larger randomized control trials (RCTs) 
are necessary to support the continued hypothesis of SPG effectiveness, the data within currently 
available literature and clinical experiences presently supports the inclusion of SPG in the 
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TABLE 1. Literature review of sphenopalatine ganglion nerve blocks. 
Authors / Article Study Design & 
Methods 
Research Question 
or Hypothesis 
Sample (n) & 
Setting 
Variables, Data Types, and 
Results 
Comments and Grade 
Cady et al. (2014). A double-blind, 
placebo-controlled study of repetitive 
trans-nasal sphenopalatine ganglion 
blockade with Tx360® as an acute 
treatment for a chronic migraine. 
Headache: The Journal of Head and 
Face Pain, 55(1), 101-116. 
 
RCT, double-blinded 
study 
0.3 ml of 0.5% 
bupivacaine using Tx 360 
device. 
Repetitive SPGNBs 
using the Tx360 devise 
with a series of 12 
SPGNBs provided 2 
times per week for 6 
weeks. 
SPGNB using Tx360 
device vs. normal saline 
placebo for treatment of 
chronic migraine 
headaches. 
n=38 
Control n= 12 
SPGNB n = 26 
Randomly 
assigned patients 
from two U.S. 
specialty 
headache clinics. 
Treatment group experienced a 
significant reduction in headaches 
vs control group at 15 and 30 
minutes (M=3.78 vs M-3.18, 
P=.10) and (M=3.51 vs M = 2.53, 
P<.001). 
From pre-treatment to final 
treatment (following 6-week 
period) the treatment group 
experienced a statistically 
significant reduction in headache 
pain vs. control (M diff = -4.52, 
P=.005) vs. (M dif = -1.5, P = .13). 
 
Statistically significant headache relief 
using the Tx360 devise for SPGNB over a 
6-week period was demonstrated. 
This study evaluated chronic migraine 
headaches specifically, not PDPHs.  
Tian Medical had no role in study design, 
subject selection or the exclusion or study 
criteria, data collection or analysis of data 
and had no role in article preparation, 
editing, review or approval. 
Grade: 2B – Recommended  
(Figure 2, Figure 3) 
 
Cardoso et al. (2017).  
Sphenopalatine ganglion block for 
postdural puncture headache in 
ambulatory setting. Brazilian Journal 
of  
Anesthesiology (English  
Edition), 67(3), 311-313.  
 
Case Report  
Cotton-tipped applicator 
saturated with 0.5% 
levobupivacaine for 5 
minutes. 
 
SPGNB versus prior 
trial with crystalloid, 
dexamethasone, 
parecoxib, Tylenol and 
caffeine. 
n=1 
41-year-old 
female 
s/p PDPH for 1 
week 
The ambulatory 
setting in Brazil 
The patient reported 0/10 pain after 
5 minutes of SPGNB. Remained 
pain-free at 1 day and 7 days post-
procedure, did have OTC pain 
medication to take at home PRN 
No mention of volume (ml) of local 
anesthetic used. Patient positioning not 
discussed. No pain relief following all 
previous non-SPGNB interventions. Pain 
relief was achieved after 1 SPGNB, no 
subsequent block or epidural blood patch 
was required. No disclosed financial 
conflicts or other conflicts of interest. 
Grade: 5D – Option (Figure 2, Figure 3) 
 
Channabasappa et al. (2017). 
Transnasal sphenopalatine ganglion 
block for the treatment of postdural 
puncture headache following spinal 
anesthesia. Saudi Journal of 
Anaesthesia, 11(3), 362. 
Case Study 
5 ml of a pre-loaded 
syringe with 0.5% 
ropivacaine attached to a 
cotton-tipped 23-g spinal 
needle. 
SPGNB was 
accomplished with 
injection vs. topical 
saturation of local 
anesthetic on ganglia. 
Will SPGNB prevent 
the need for epidural 
blood patch in PDPH 
parturient? 
n=1 
PDPH following 
combined spinal-
epidural for C-
section in 
hospital in India 
 
Instantaneous and sustained pain 
relief. 24 hours post-procedure, the 
patient remained pain-free and 
follow-up at 3 weeks post-
procedure revealed continued pain-
free scores. 
The patient initially treated with 
conventional fluids, NSAIDS, caffeine and 
bed-rest, all with no effect. 
Injection of LA vs. topical saturation 
increases the risk of bleeding, infection 
and painful injection in a sensitive area. 
N=1 with no controls merits further study 
needed to substantiate these findings. 
Financial interests not disclosed. 
Grade: 5D – Option (Figure 2, Figure 3) 
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TABLE 1. - Continued 
Authors / Article Study Design & 
Methods 
Research Question 
or Hypothesis 
Sample (n) & 
Setting 
Variables, Data Types, 
and Results 
Comments and Grade 
Cohen et al. (2009). 
Sphenopalatine ganglion block for 
postdural puncture headache. 
Anaesthesia, 64(5), 574-575. 
 
Case Series 
Cotton-tipped applicator 
soaked with 4% lidocaine 
ointment 
SPGNB effectiveness on 
1st vs. subsequent blocks 
n=13 
Unknown setting 
11 of the 13 patients 
received immediate and/or 
complete relief following 
1st SPGNB (84.6% reported 
success) 
Small case series reported in an editorial format 
Patients were given the option for blood patch 
or SPGNB. 
Controls for trial were not discussed 
The two patients that did not receive relief with 
first SPGNB were taught to self-administer 
blocks at home once per day, up to a week in 
duration. 
Grade: 5D – Option (Figure 2, Figure 3) 
 
Cohen et al. (2014).  
Sphenopalatine ganglion block. 
Regional Anesthesia and Pain 
Medicine, 39(6), 563. 
 
Case Series 
Cotton-tipped applicator 
saturated with 5% water-
soluble lidocaine ointment. 
Left in place for 10 
minutes. 
SPGNB effectiveness 
for treatment of PDPH 
amongst obstetric 
patients, eliminating the 
need for epidural blood 
patch. 
n=32 
Obstetrical patients 
suffering from 
PDPH following 
accidental dural 
puncture from a 17-
gauge epidural 
needle. 
69% reported success in 
relieving PDPH by use of 
SPGNB amongst 32 
obstetric patients, 
eliminating the need for an 
epidural blood patch. 
Case series. Controls and other possible 
interventions not discussed. 
These authors continue in subsequent literature 
to report their continued successes with 
SPGNB. Editorial concludes by saying: “In 
conclusion, we recommend that every patient 
with a PDPH receive the minimally invasive 
SPGNB, which is most cases can avoid the 
need for an EDBP and its potential 
complications.” 
Grade: 4C – Option (Figure 2, Figure 3) 
 
Cohen, S., Trnovski, S., & Zada, 
Y. (2001). A new interest in an 
old remedy for a headache and 
backache for our obstetric 
patients: A sphenopalatine 
ganglion block. Anesthesia, 56(6), 
606-607. 
 
Case Report 
Cotton-tipped applicator 
saturated with EMLA 
cream for 10 minutes 
(2 of the 22 patients could 
not tolerate the EMLA 
cream; they were given 
Cetacaine nasal spray. 
SPGNB for treatment of 
moderate to a severe 
backache or a headache 
amongst obstetrical 
patients. 
n=22 
Obstetrical patients 
complaining of 
moderate to severe 
backache and 
headache during a 
hospital stay. 
100% of patients 
experienced complete relief 
of pain within 6-10 minutes 
of SPGNB procedure. 
No side-effects reported 
amongst any of the n=22 
participants. 
A limited case report of 22 patients is reported 
in an editorial, abstract format. Qualifying data, 
weaknesses, financial interests were not 
disclosed. 
No control, not randomized or blinded. Further, 
larger studies are needed to support the 
hypothesis of SPGNB effectiveness further. 
Grade: 5D – Option (Figure 2, Figure 3) 
 
Kent, S., & Mehaffey, G. (2016). 
Transnasal sphenopalatine 
ganglion block for the treatment 
of postdural puncture headache in 
obstetric patients. Journal of 
Clinical Anesthesia, 34, 194-196 
Case Report 
2% viscous lidocaine on 
long, cotton-tipped 
applicators, left in place for 
10 min, then additional 2% 
lidocaine reapplied and 
applicator re-inserted for 
additional 20 min 
SPGNB effectiveness in 
obstetric patients 
suffering from PDPH. 
Will the SPGNB avoid 
the need for epidural 
blood patch? 
n=3 
Labor and Delivery 
Suite. Post-partum 
obstetrical patients 
suffering from 
PDPH 
All three patients had 
“significant” relief from 
PDPH following SPGNB 
and all three avoided the 
need for epidural blood 
patch. 
An initial headache vs. 
post-SPGNB headache 
scores as follows: 
Patient 1. 9/10 to 0/10 
Patient 2. 8/10 to 0/10 
Patient 3. 9/10 to 0/10 
Small case report. Patients were discharged 
following SPGNB with instructions to drink 
plenty of fluids and include caffeinated drinks. 
None of the three patients required subsequent 
treatment.  
No conflicts of interest disclosed. 
A larger study is needed. 
Grade: 5D – Option (Figure 2, Figure 3) 
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TABLE 1. - Continued 
Authors / Article Study Design & 
Methods 
Research Question or 
Hypothesis 
Sample (n) & 
Setting 
Variables, Data Types, and Results Comments and Grade 
Patel, P., Zhao, R., 
Cohen, S., Mellender, 
S., Shah, S., & Grubb, 
W. (2016). 
Sphenopalatine 
ganglion block (SPGB) 
versus epidural blood 
patch for accidental 
postdural puncture 
headache (PDPH) in 
obstetric patients: A 
retrospective 
observation. The 
American Academy of 
Pain Medicine, 
Abstract 145, 1. 
 
Retrospective 
observational study 
over a 17-year 
period (Abstract 
Only) 
Epidural blood patch vs 
SPGNB for PDPH  
n=72 
n=33 SPGNB 
n=39 = epidural 
blood  
patch 
Patients with no 
previous history of 
primary headache 
disorders who were 
experiencing PDPH 
Retrospective data analysis of 72 records 
spanning 17 years. No differences in ASA 
scores, patient age, height, weight or BMI 
At 24 hours post-treatment, no difference 
in pain scores amongst SPGNB and 
epidural blood patch group. 
SPGNB group experienced improved 
headache scores at 30 min post procedure 
vs epidural blood patch (54.55% relief vs. 
20.51%) and at 60 minutes post procedure, 
SGNB group had 63.64% relief vs. 
30.77% for epidural blood patch group. 
SPNB group had no complications, versus 
the epidural blood patch group had nine 
patients return to ED for complications. 
 
Abstract report of a retrospective observational 
study. The details of this study were never 
published, thus limiting the information and 
analysis of data that was presented in abstract form. 
The SPGNB group had better relief with fewer 
side-effects vs. the epidural blood patch group. 
Continued, fully-published and disclosed studies of 
this nature would be helpful to further support the 
use of SPGNBs for the treatment of PDPHs. 
Grade: 3C – Option (Figure 2, Figure 3) 
 
Schaffer, J., Hunter, 
B., Ball, K., & Weaver, 
C. (2015). Noninvasive 
sphenopalatine 
ganglion block for 
acute headache in the 
emergency department: 
A randomized placebo-
controlled trial. Annals 
of Emergency 
Medicine, 65(5), 503-
510. 
Randomized, 
Placebo-Controlled 
Trial  
Tx360 devise for 
application of 
SPGNB using 0.3 
ml of 0.5% 
bupivacaine 
delivered by the Tx 
360 device.  
SPGNB vs. placebo 
treatment for acute 
headache in the ED. 
The hypothesis was that 
the Tx360 SPGNB devise 
would achieve a 50% 
reduction in anterior 
headache pain vs. saline 
placebo delivered using 
same technique at the 15-
minute post-procedure 
mark. 
n=93 
Control n = 48 
SPGNB n = 45 
Two large academic 
emergency 
departments of 
Level 1 facilities 
between Oct 2012 
to Oct 2013 
The treatment group n=45 did not 
experience a statistically significant 
improvement (risk difference of 7.5% with 
95% CI) at the 15-minute mark and 
secondary outcomes revealed similar 
nausea scores at 15 minutes post-
procedure (risk difference of 3.5% with 
95% CI of 15.3% vs. 21.8%).  
Post-24-hour follow-up revealed treatment 
group was a headache free (with a 
statistical significance) with 72.2% vs. 
47.5% for the control group. 
RCT was funded in part by Tian Medical LLC who 
is the manufacturer of the Tx360 device; however, 
Tian Medical had no role in the study design, 
subject selection or the exclusion or study criteria, 
data collection or analysis of data and had no role 
in article preparation, editing, review or approval. 
Further studies are needed using alternative 
techniques. This study did not support the 
hypothesis of SPGNB effectiveness at the 15-
minute post-procedure mark, however, it did 
provide some supportive secondary data that was 
significant and merits further study, including post-
procedure nausea and reduced headache pain at the 
24-hour post-procedure mark. 
Grade: 2C – Option (Figure 2, Figure 3) 
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Level Type of evidence
1A Systematic review (with homogeneity) of RCTs
1B Individual RCT (with narrow confidence interval)
1C All or none study
2A Systematic review (with homogeneity) of cohort studies
2B Individual cohort study (including low quality RCT)
2C "Outcomes" research; Echological studies
3A Systematic review (withhomogeneity) of case-control studies
3B Individual case-control studies
4 Case series (and poor quality cohort and case-control studies)
5 Expert opinion; case report or clinical example; or evidence based on physiology
Burns, P., Rochrich, R., Chung, K. (2011). The levels of evidence and their role in 
evidence-based medicine.  Plastic and Reconstructive Surgery, 128(1), 305-310.
Reprinted with permission.
Grade Descriptor Qualifying Implications for Practice
Evidence
A Strong Level 1 evidence or Clinicians should follow strong
recommendation consistent findings recommendations unless clear or compelling
from multiple rationale for an alternative approach is present
studies of levels II, 
III, or IV
B Recommendation Levels II, III, or IV Generally, clinicians should follow a
evidence and recommendation but should remain alert to new
findings are information and sensitive to patient preferences
generally consistent
C Option Levels II, III, or IV Clinicians should be flexible in their decision-
evidence, but making regarding appropriate practice, although
findings are they may set bounds on alternatives; patient
inconsistent preference should have a substantial influencing
role
D Option Level V evidence; Clinicians should consider all options in their
little or no decision making and be alert to new published
systematic empirical evidence that clarifies the balance of benefit 
evidence versus harm; patient preference should have a
substantial influencing role
Burns, P., Rochrich, R., Chung, K. (2011). The levels of evidence and their role in evidence-based medicine.  
Plastic and Reconstructive Surgery, 128(1), 305-310. Reprinted with permission.
treatment of PDPH, especially in light of the relative ease, low risk, low cost and effectiveness of 
this intervention (Fulkerson, 2017). 
Weaknesses 
Large, randomized control trials on the effectiveness of SPG blocks for the treatment of 
PDPH are limited and more research is needed; however, the evidence obtained even in these 
smaller case studies may be significant, especially when pooled together. The majority of current 
studies reported in the literature supporting SPG blocks have a level of evidence ranging from 
2B to 4D (Figure 2, Figure 3). 
 
 
 
 
 
FIGURE 2. Adaptation of levels of evidence for therapeutic studies. 
 
 
 
 
 
 
 
FIGURE 3. Adaptation of grade practice recommendations. 
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Higgs, Burn, and Jones (2001) emphasize the value of data gleaned and pooled from 
smaller data sets. This approach supports the argument for including SPGNBs for the treatment 
of PDPH.  
Gaps 
The most significant gap discovered during the literature review process was the lack of 
current, large, well-designed trials supporting the hypothesis of SPGNB inclusion for the 
treatment of PDPHs. Also identified was the frequent lack of standardized care and failure to 
follow a clinical practice guideline for treatment of PDPH. There was virtually no literature 
contradicting or failing to support the use of SPGNB in some way, however, the suggestion or 
recommendation for its inclusion in the guidelines for treatment of PDPH continues to be 
elusive. This gap between knowledge and clinical practice was at the heart of this DNP project, 
which sought to update clinical practice guidelines to reflect best practices supported by the 
literature and inform local anesthesia providers regarding this information. 
Synthesis of Evidence 
Of the 11 original studies and reports selected for analysis and synthesis (Table 1), five 
were case reports, three were case series, two were RCTs and one was a retrospective 
observational study. Synthesis of the literature generally supported the effectiveness of SPGNBs 
for the treatment of both PDPH and the more generalized headache pain syndromes of various 
etiologies (Table 1). 
Cohen, Sakr, Katyal, and Chopra (2009) and Cohen et al. (2014) describe two case series 
and one case report with impressive results (84.6% & 69% success rates, respectively) from 
SPGNBs. The SPGNB technical procedures vary considerably amongst the various reports and 
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studies reviewed, further contributing to perhaps a disparity in outcomes. The most recent 
information that is being presented at conferences reflecting the highest success rate involves the 
use of 4% liquid lidocaine on cotton-tipped applicators left in place for 30-60 minutes. 
Table 1 outlines and grades 11 recent studies, reports and RCTs reporting original data 
which provide support for the success of SPGNBs for the treatment of PDPH; however, further, 
more extensive and better-controlled trials are needed to validate this data. Patel et al. (2016) 
reported on a 17-year retrospective observational study involving 72 patients that were 
randomized into two groups — SPGNB intervention versus epidural blood patch intervention for 
PDPH. At the 30-minute post-procedure mark, the SPGNB group had a statistically significant 
reduced pain score (54.55% relief versus 20.51%) and at 60 minutes’ post-procedure, the 
SPGNB group had 63.64% relief versus 30.77% for the epidural blood patch group (Patel et al., 
2016). 
Cady et al. (2014) in their double-blinded RCT (n=38), reported a statistically significant 
reduction in migraine headache pain versus the control group (mean difference = -4.52, P = .005) 
versus (mean difference = -1.5, P = 0.13). This study, while demonstrating the effectiveness of 
SPG blocks for the treatment of migraine headaches following a six-week evaluation period, did 
not specifically address postdural puncture headaches. This study was also specifically 
evaluating a commercially available device designed for application of SPGNG manufactured by 
Tian Medical called the Tx360 (Cady et al., 2014). 
Another RCT authored by Schaffer, Hunter, Ball, and Weaver (2015) was also evaluating 
the effectiveness of the TX360 devise versus placebo for treatment of patients with acute 
headaches presenting in the emergency department. This study (n=45) did not provide a 
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statistically significant difference between treatment and control groups in headache reduction at 
the 15-minute post-treatment mark, however it did provide a statistical reduction in headache 
pain when evaluated at the 24-hour post-intervention mark (72.2% reduction in pain for 
treatment group versus 47.5% reduction for the control group) (Schaffer et al., 2015). 
While larger studies are still lacking, the cumulative support from smaller data points 
provide support for the inclusion of SPGNBs for the treatment of PDPH, based on current 
literature. Higgs et al. (2001, p. 488) argued that evidence-based practice should not be based on 
a “cookbook” approach, but rather, embrace a broader approach including not only the latest 
literature but also inclusion of professional judgment, practice experiences and critical thinking. 
METHODS 
Project Design 
The purpose of this project was to modify and disseminate a clinical practice guideline 
(CPG) for the treatment of PDPH adapted for the Anesthesia Physicians of Arizona’s (APA) 
anesthesia providers practicing at Mountain Vista Medical Center (MVMC). This project 
included a comprehensive and systematic approach to the literature review, consultation with on-
sight anesthesia experts regarding existing practices, CPG modification and validity assessment, 
and presentation to a local facility for implementation consideration. Information gained from 
the literature and assessment of current clinical practice was used to inform the modified 
guidelines. The original NYSORA CPG for the treatment of PDPH and published on the 
NYSORA website were reviewed and selected for CPG modification (Harrington & Reina, 
2019). 
   
32 
The newly modified CPG was specifically created for utilization by APA anesthesia 
providers at the local facility. Comparisons of the original and modified CPG were conducted by 
two anesthesia providers using the AGREE II instrument (Brouwers et al., 2010) (Appendix F). 
Those participating in the AGREE II assessment first completed an online training module 
provided by the AGREE II Trust and attested to their training by signing the AGREE II 
Appraiser Training Confirmation document (Appendix G), affirming they have completed the 
standardized online training for the use of the AGREE II scoring instrument. 
Development and modification of the clinical practice guideline within this DNP project 
were intended to strengthen the AGREE II score from the original NYSORA CPG, strengthening 
each of the domains where weaknesses were identified. The implementation and dissemination 
portion of this project included the presentation of the newly modified CPG and data input 
results and AGREE II scores to the anesthesia department stakeholders from APA practicing at 
the local facility and a poster presentation to the CRNA community at a local conference in 
March 2019. Feedback and analysis of data were obtained using a standardized Pre- and Post-
CPG Modification AGREE II Scores Form (Appendix D). 
Setting 
The setting for this DNP project was the anesthesia department at the local facility where 
anesthesia providers from Anesthesia Physicians of Arizona (APA) practice anesthesia. The local 
facility is a 178-bed, community-based hospital serving the residents of a suburb within the 
metro Phoenix, Arizona community and surrounding cities. The Anesthesia Physicians of 
Arizona (APA) provides anesthesia services at the local facility serving their surgery department, 
which operates 10 operating rooms, a cardiac catheterization laboratory consisting of two 
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interventional suites, the endoscopy department comprised of two procedure rooms, and the 
obstetrical department which consists of one general anesthesia operating room and 
administration of epidural and spinal anesthesia to that hospital population. The APA practice 
was selected for project presentation due to: 1) close geographical proximity to the author of this 
project; and, 2) familiarization with this anesthesia clinical rotation site by the author. A site 
approval letter was signed on June 9, 2018, by Dr. Ned Sciortino who serves as the medical 
director for APA at the local facility clinical site (Appendix G). 
Participants 
There are approximately 32 full-time and part-time APA anesthesia providers at the local 
facility, including primarily CRNAs and a few physician anesthesiologists. Two local anesthesia 
providers were invited to participate in the AGREE II CPG review process and four on-site 
anesthesia providers were invited to provide consultation, input and feedback.  
Intervention and Dissemination 
The intervention and dissemination element of this DNP project involved the presentation 
of the newly modified CPG for the treatment of PDPH for local application by APA anesthesia 
providers at the local facility, along with the AGREE II validity data and summary of qualitative 
data from local industry experts gained throughout the process of the SPGNB literature review 
and CPG modification process. Summary qualitative data was included in the presentation and 
dissemination portion of this project. Dissemination also involved a poster presentation on the 
topic to the local CRNA community at an annual anesthesia conference in Scottsdale, AZ. 
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Tools 
The Agree Reporting Checklist (Appendix J) was one of the primary tools used for the 
evaluation and reporting of the CPG referenced within this DNP project. Additional tools used 
included a Consult Input Form (Appendix D), and a Stakeholder Feedback Form (Appendix I). 
Data Collection Process 
This DNP project followed a systematic review of the literature supporting the use of 
SPGNB. Assessing the original and modified CPG followed the AGREE II Reporting Checklist, 
which guides the process of data collection (Appendix H). Two project participants were selected 
to be trained in AGREE II evaluation methods and then asked to appraise this modified PDPH 
CPG. Following final presentation to APA stakeholders practicing at the local facility, feedback 
was obtained and analyzed using the Stakeholder Feedback Form (Appendix I). 
Data Analysis  
Quantitative data was collected and analyzed as part of this project. Qualitative data was 
gathered from local industry expert consultants at the local facility. Data from the AGREE II 
CPG assessments were analyzed and summarized, addressing the pre- and post-CPG 
modification for quality, validity, clarity, applicability, and independence. This tool utilizes a 
seven-point Likert-scale to evaluate 23 individual CPG items within six domains (Brouwers et 
al., 2010).  
Ethical Considerations 
Respect for Persons 
This project was submitted to the University of Arizona’s College of Nursing for 
Institutional Review Board (IRB) consideration using the standardized Human Research Form 
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(Consent Templates | Research Gateway, 2018). This DNP project was not defined as research or 
research involving human subjects. A Determination of Human Research exemption was granted 
(Appendix K), therefore a full IRB application and approval process was not necessary (45 CFR 
46 – Protection of Human Subjects, 2018). 
Each participant, consultant, and stakeholder involved in this DNP project was on a 
voluntary basis. This project contained no discussions, considerations or questions relating to 
age, ethnicity, religion or sexual orientation. Confidentiality and data security was maintained 
through use of a secure, password-protected hard drive. 
Beneficence 
There were no risks, including financial, emotional or safety risks associated with this 
project. The project did not involve human subject studies or trials. Benefits from this DNP 
project include increased knowledge and awareness of literature and professional consultant 
support for CPG revision for the treatment of PDPH. The APA anesthesia stakeholders 
practicing at the local facility also benefited from having an updated clinical practice guideline 
that can be implemented, at their discretion, to treat patients suffering from PDPH with the latest 
evidence-based protocols. 
Justice 
Following the CPG presentation, feedback from APA anesthesia stakeholders practicing 
at the local facility provided valuable data to assure the presentation of the material was deemed 
to meet this project’s objectives. This project did not involve human subject studies, recruitment 
or human data collection. All those involved in this project, including the DNP committee 
members, expert consultants, and stakeholders, participated on a voluntary basis without regard 
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to any discriminatory or financial interest factors. The APA anesthesia stakeholders practicing at 
the local facility were selected as the beneficiary of this project solely due to geographical 
convenience and clinical rotation scheduling. There were no financial, educational, economic or 
professional conflicts, disclosures or known ancillary affiliations related to this DNP project that 
would create a conflict of interest. 
RESULTS 
Following tabulation of the pre- and post-CPG modification AGREE II scores (Appendix 
D) and input from local expert consultants (Appendix E), the NYSORA CPG for the treatment of 
PDPH was modified (Appendix B) and a more simplified algorithm was developed for 
presentation and implementation consideration by stakeholders at the local facility (Figure 4).  
Brouwers et al. (2010) suggest a minimum of two trained evaluators are needed to 
complete the AGREE II scoring tool of a CPG to assess its rigor, quality, and transparency 
adequately. Two anesthesia providers practicing at the local facility were invited to participate in 
the AGREE II appraisal process. Each provider was given a copy of the Appraisal of Guidelines 
for Research & Evaluation II, which outlines detailed instructions on how to accurately score a 
CPG using the AGREE II tool (Brouwers et al., 2010). Additionally, each appraiser completed 
an online training tutorial provided by the AGREE II Trust (Brouwers et al., 2010) and attested 
to the completion of such training (Appendix F) 
Overall, 23 key elements were assessed across six domains, as well as two broad, overall 
assessments comparing the original and modified CPG. The six domains included: Scope and 
Purpose, Stakeholder Involvement, Rigour of Development, Clarity of Presentation, 
Applicability, and Editorial Independence; the two broad assessments included Overall Quality 
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and Overall Guideline Assessment (Brouwers et al., 2010). The goal of this assessment was to 
provide an answer to the study question as to whether local stakeholders would score the revised  
FIGURE 4. Modified New York School of Regional Anesthesia (NYSORA) postdural puncture 
headaches treatment flow chart.  
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CPG, which includes the recommendation for using an SPGNB for the treatment of PDPH, as 
equal or higher quality than the original unmodified NYSORA CPG for the treatment of PDPH. 
Overall, the modified CPG received higher scores in each of the six domains, with an 
overall increase from 55% to 80%, providing an affirmative answer to the study question. 
Domain 1, Scope and Purpose, increased from 64% to 97%. Domain 2, Stakeholder 
Involvement, increased from 44% to 86%. Domain 3, Rigour of Development was scored 49% 
initially and 86% for the modified CPG. Domain 4, Clarity of Presentation, went from 86% to 
94%. Domain 5, Applicability, increased from 54% to 67% and Domain 6, Editorial 
Independence, increased from 38% to 42%. 
Figure 5 reflects the summary data across each of the six domains and highlights the 
improvements within each category; blue represents the pre-modification scores and orange 
represents the post-CPG modification scores.  
 
 
 
 
 
 
 
FIGURE 5. Improvement in CPG scoring. 
Four expert anesthesia consultants practicing at the local facility provided input relating 
to the various treatment modalities for PDPH and their inclination to include or exclude specific 
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treatment modalities at the local level of their practice. The consultants were asked to consider 
ten treatment modalities identified within the original NYSORA CPG and consider which of 
these they would be most inclined or least inclined to consider for the treatment of PDPH at the 
local facility. Treatment considerations included: 1) bed rest; 2) hydration with IV or PO fluids; 
3) use of aminophylline, theophylline or caffeine; 4) use of serotonin type 1d receptor agonists 
such as sumatriptan; 5) use of ergot alkaloids such as methylergonovine; 6) use of 
corticosteroidogenics such as cosyntropin/tetracosactin; 7) use of corticosteroids such as 
hydrocortisone; 8) use of anticonvulsants such as gabapentin; 9) application of a sphenopalatine 
ganglion nerve block; and, 10) epidural blood patch (Appendix D). The summary results of the 
expert recommendations were included in the local facility Anesthesia Provider Preferences 
(Figure 6). Of particular interest and applicability to this DNP project was that 100% of the 
expert consultants indicated they would consider the inclusion of SPGNB for the treatment of 
PDPH.  
This data and local expert recommendation further strengthen the argument to include 
consideration for SPGNB for the treatment of PDPH in the CPG modification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. The local facility anesthesia provider preferences. 
            Provider              1                                 2                                  3                                4 
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DISCUSSION 
Modification of the NYSORA CPG for the treatment of PDPH to include SPGNB 
provides anesthesia stakeholders and practitioners at the local facility a locally applicable, high-
quality clinical practice guideline for implementation consideration. This study’s question is 
addressed and answered in the affirmative; the AGREE II assessment of the modified CPG was 
scored 45% higher (80% versus 55%) than the original NYSORA CPG. This finding was 
important for several reasons. Current practices for the treatment of PDPH have been 
inconsistent, and CPGs on the topic have failed to include SPGNB, even though there is 
emerging evidence within the literature and a plethora of positive anecdotal experiences amongst 
anesthesia practitioners regarding its success. Anesthesia practitioners at the local facility have 
not had a standardized CPG at their institution for the treatment of PDPH. The results of this 
DNP project provide the local facility a systematic, stepwise approach which includes the low-
risk, less-invasive SPGNB before attempting more aggressive interventions for the treatment of 
PDPH. Healthcare facilities rely on clinical practice guidelines that are adapted to their 
preferences, needs, and goals. This DNP project provides the local facility such a locally adapted 
CPG. The input and practice preferences provided by the four local anesthesia experts from the 
local facility further addresses the preferences, practices, and experiences of their local 
providers. 
The modified CPG presented to stakeholders at the local facility addressed numerous 
areas of focus identified as weaknesses in the original NYSORA CPG. Additional clarity was 
provided under the following headings: objectives, CPG modification question, target 
population, intended users, overall modifications and recommendations, literature-based 
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evidence and strength of evidence/grading, a simplified algorithm, a review of the pre- and post-
AGREE II scoring, updating procedures, stakeholder involvement, facilitators and barriers to 
implementation, and funding/conflict of interest. There are multiple ways of administering a 
successful SPGNB, and the literature varies significantly on the topic. It was not the objective of 
this DNP project to delve into this specific question and explore the nuances of various 
techniques, however, there was a consensus of expert opinion that was provided as a brief 
suggestion to the stakeholders at the local facility which does appear to reflect current best 
practices amongst practitioners experienced with SPGNB. 
Stakeholders at the local facility should remain cognizant that this topic is one of 
emerging fluidity and there will likely be new information, studies, and expert opinion that may 
either reinforce or contradict some of the modifications suggested within this DNP project’s 
modified CPG. There have been considerable recent discussions on the topic of SPGNB for the 
treatment of PDPH at anesthesia conferences and seminars and some indication that more on the 
topic will soon be reflected and addressed in upcoming anesthesia textbooks. 
Dissemination Plan 
The goal of this DNP project was to provide a local facility a modified clinical practice 
guideline for the treatment of PDPH that provides for the early consideration for the lesser-
invasive SPGNB. Translating evidence into practice is often a challenging task, taking up to 
seventeen years to overcome the status-quo and various implementation barriers (Morris et al., 
2011). Fundamental to overcoming these barriers is the incorporation of local influence agents 
who have the respect of their peers and can provide some level of peer support and energy to 
overcome the status quo. Four anesthesia experts practicing at the local facility were sought out 
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early and involved in the process of providing insight and expert consultation. The original 
NYSORA CPG and the modified CPG for the treatment of PDPH were assessed using the 
AGREE II instrument by the local facility anesthesia providers as well, providing an element of 
local applicability. Moreover, the presentation of the modified CPG and the supporting data and 
AGREE II scoring was presented to the Medical Director of Anesthesia at the local facility and 
the chief CRNA. The modified CPG was presented to the stakeholders at the local facility 
(Appendix B) providing a simple-to-implement guideline at their local level for the treatment of 
PDPH. Included was the expert input from four of their anesthesia providers and the summary 
AGREE II scoring data from two of their anesthesia providers. Further dissemination of this 
modified PDPH CPG and the literature supporting the early consideration for SPGNB was 
presented in the form of a poster presentation at an annual state CRNA conference in March 
2019. 
Following the presentation and discussion of the modified CPG for implementation at the 
local facility, feedback was obtained from the two main anesthesia stakeholders at the local 
facility using a standardized Stakeholder Feedback Form (Appendix G). Summarizing this data, 
both the director of anesthesiology and their head CRNA indicated that they would recommend 
the modified CPG for approval as a clinical practice guideline at their institution and, if and 
when approved, they would apply the CPG recommendations to their patients. Having both the 
stakeholder and local anesthesia experts and change agents involved throughout this process will 
hopefully bode well for translation into practice at the local facility. 
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Strengths, Weaknesses and Limitations 
The strength of this DNP lies within the premise that evidence-based practice is not only 
those practices that are strongly supported within the literature with highly-rated and graded 
research but also those practices that reflect sound clinical judgment based upon practitioner 
experiences and consensus expert opinions (Nguyen & Walters, 2014). Often, this is how new 
best practices evolve. In fact, many of the practices and interventions used today by anesthesia 
providers are not yet fully supported by large, randomized, double-blind studies, simply due to 
the ethical nature and difficulty of these studies, yet are still accepted as best practices and 
supported amongst the experts within the field (Nguyen & Walters, 2014). Another strength of 
this project is the notion that a locally adapted clinical practice guideline, reviewed and accepted 
by the key stakeholders and change agents, has been reviewed, graded and accepted as a viable, 
suitable, and appropriate CPG for their facility. Baysinger, Pope, Lockard, and Mercaldo (2011) 
report that nationally, only 14% of practitioners are routinely following clinical practice 
guidelines in their patient care. It is also reported by Eccles and colleagues (2012) that 
approximately 40% of patient care in the U.S. today does not reflect known best practices and as 
many as 25% of patient care interventions are known to be ineffective. Providing the anesthesia 
practitioners at the local facility a CPG for the treatment of PDPH that they can systematically 
follow standardizes the care based on currently available best-known practices. Additionally, the 
revised CPG provides a benefit to patients at the local facility suffering from PDPH in that they 
now have an option for a less-invasive intervention which may potentially eliminate the need for 
an epidural blood patch. 
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Weaknesses of this DNP project include the fact that this modified CPG is not yet 
strongly supported by robust, randomized, multi-institutional highly-graded studies. The 
modified CPG produced as a result of this project also was the product of a single DNP student 
without any direct human subject data collection. This project was not directed at generating new 
knowledge; it was focused on compiling broadly discriminated current knowledge and practices 
into a single point for CPG modification and local implementation. The author of this DNP 
project, as a clinical student at the local facility, lacked the positional authority and formal 
influences needed for the policy changes required for CPG implementation; however, the tools 
and information were presented to stakeholders at the local facility with such authority so they 
can continue and follow-through to full implementation at their discretion. 
An additional weakness of this DNP project was the limited use of AGREE II appraisers. 
The AGREE II guidelines recommend a minimum of two and a maximum of four appraisers. 
Due to limited resources at the local facility, two appraisers were used for this assessment which 
potentially provides some limitations in the quality of CPG assessments completed. In an attempt 
to mitigate this limitation, the two appraisers were required to complete the online AGREE II 
tutorial and review the printed AGREE II instructions before their assessments. 
Incorporation of DNP Essentials 
The American Association of Colleges of Nursing (2006) mandates eight essential 
education requirements within every DNP program. This DNP project incorporated several of 
these DNP essential elements as follows: Essential I, scientific underpinnings for practice were 
incorporated through the identification of and use of scientific practices involved in research, 
literature review and grading of evidence. Anatomy and physiologic processes were identified as 
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the cause of PDPH and the reasons why SPGNB are often effective in eliminating the symptoms; 
Essential III, clinical scholarship and analytical methods for evidence-based practice was at the 
heart of the entire project, seeking out best practices both within the literature and amongst 
expert practitioners, the use of analytical tools such as the AGREE II CPG assessment 
instrument, and various other data collection and analytical methods incorporated within this 
project; Essential VI, interprofessional collaboration for improving patient and population 
health outcomes was incorporated into this DNP project as well. A project team was formed 
consisting of faculty from the University of Arizona’s College of Nursing and expert anesthesia 
consultants and stakeholders at the local facility were involved as well throughout the duration of 
the project; finally, DNP Essential VIII, advanced nursing practice focuses on this DNP author’s 
newly gained knowledge and expertise in the specialty field of nurse anesthesia and the 
application of this knowledge in identifying a specific clinical problem and presenting a viable, 
evidence-based solution to address it. 
Conclusion 
Patients suffering from postdural puncture headaches and those treating them have been 
at odds for some time as to the best, most efficacious treatment options. While the 
sphenopalatine ganglion nerve block has been used for decades to treat a wide variety of other 
headache maladies, the bridge to using this option for treating PDPH has been elusive. Of late, 
increasing experiences and reports in the literature are supporting the use of SPGNB for the 
treatment of PDPH before attempting an epidural blood patch, as has been the increasing 
accumulation of expert opinions on the topic. Translating best-known practices into CPGs and 
implementing them for standardized care, however, is often difficult, time-consuming, and met 
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with a multitude of obstacles. This project identified a local institution where they lacked a CPG 
for the treatment of PDPH, identified a problem with inconsistent treatment regimens and 
practices that perhaps did not always reflect best practices, and it provided a solution to their 
problem. The study question as to whether local stakeholders would find a revised CPG that had 
been crafted and locally adapted to suit their local goals, needs, and preferences to be of higher 
quality than a nationally published CPG for the treatment of PDPH was answered in the 
affirmative. The result of this DNP project was the presentation of a much-improved clinical 
practice guideline for the treatment of PDPH which included the early consideration of SPGNB. 
As an advanced practice nurse specializing in nursing anesthesia and completing a DNP 
degree at the University of Arizona, this author was pleased to be able to participate in a project 
that produced a locally-adapted, high-quality CPG ready for implementation at the local facility 
which will provide more consistent care based upon current literature and emerging expert 
consensus opinion. Translating evidence and knowledge into practice is often a long, difficult 
process and through the incorporation of a team-based approach, the use of Lewin’s change 
theory and inclusion of local practitioners as potential change agents, the stage has been set for a 
successful implementation. 
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APPENDIX A: 
NYSORA CPG FOR THE TREATMENT OF POSTDURAL PUNCTURE HEADACHES 
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Website link to the NYSORA’s CPG for the treatment of postdural puncture headaches: 
https://www.nysora.com/foundations-of-regional-anesthesia/complications/postdural-puncture-
headache 
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APPENDIX B: 
MODIFIED NYSORA CLINICAL PRACTICE GUIDELINE 
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Modification of NYSORA Clinical Practice Guideline 
for Treatment of Postdural Puncture Headache 
Adapted for Anesthesia Physicians of Arizona practicing at 
Mountain Vista Medical Center, Mesa, AZ 
 
Report Date: October 12, 2018 
 
Scope and Purpose 
 
Objectives 
 
This modified Clinical Practice Guideline (CPG) is intended to provide updated, evidence-based 
practice recommendations to the anesthesia providers practicing at Mountain Vista Medical 
Center (MVMC) for the treatment of postdural puncture headaches (PDPH). Combining current 
literature-based evidence on the topic, along with input from expert consultation from local 
anesthesia experts, this modified CPG has been specifically adapted for implementation at 
MVMC in Mesa, AZ. Specifically, the introduction of early consideration for use of a 
sphenopalatine ganglion nerve block will provide anesthesia providers and their patients a 
minimally-invasive option for treating PDPH.  
 
CPG modification Questions 
 
Is there an effective, minimally-invasive intervention option (versus the gold-standard Epidural 
Blood Patch) for the treatment of Postdural Puncture Headache for patients at Mountain Vista 
Medical Center? Is there evidence supporting the early consideration for a Sphenopalatine 
Ganglion nerve block prior to attempting more invasive techniques? Considering expert 
consultation input from anesthesia providers at Mountain Vista Medical Center, what are their 
preferences for treatment of Postdural Puncture Headache? Based upon currently available 
industry expert consensus, what is the optimal technique for performing an SPG nerve block that 
can be implemented at Mountain Vista Medical Center? 
 
Target Population 
 
Intended patient population for this CPG modification includes adult patients, 18-years of age or 
older, who are suffering from a postdural puncture headache at Mountain Vista Medical Center. 
While the majority of these patients are likely to include the obstetrical population, this guideline 
is not limited solely to the OB population. Adult patients who have received either a diagnostic 
spinal tap or spinal anesthetic or for those patients that may been administered an epidural 
injection or catheter placement for non-OB related reasons with inadvertent dural puncture 
resulting in postdural puncture headache. 
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Intended Users 
 
This modification to the NYSORA CPG for treatment of postdural puncture headache is 
intended for local implementation by anesthesia providers practicing at Mountain Vista Medical 
Center in Mesa, AZ.  
 
Overview of Modifications and Recommendations 
 
This supplemental modification to the NYSORA CPG for the treatment of postdural puncture 
headache has focused primarily on suggesting the addition for early consideration for an SPG 
block prior to attempting the more invasive epidural blood patch. Additionally, the original 
NYSORA treatment algorithm (decision tree) has been modified to: 1) make it easier to follow 
and 2) introduce the SPG step as an early consideration. Finally, a section has been added 
covering expert consensus opinion on the SPG procedure itself which can be implemented at 
MVMC.  
 
 
1. Based upon patient presentation, severity of symptoms, prior modalities already 
attempted and anesthesia provider experience and preference, consider the option for 
early SPG block prior to attempting more invasive Epidural Blood Patch. 
 
 
2. Recommended SPG block technique. Multiple techniques for administering an SPG 
block have been attempted with varied results. Based upon expert consensus and the 
most recently available information, the following points are recommended to maximize 
results (Rigdon, S., 2017). 
 
a.  1-3 ml (slowly over 30-60 min) of 4% lidocaine (per side) is preferred versus 2% 
lidocaine or other topical anesthetics 
b. Use cotton-tipped, hollow-tubed culture swabs soaked in 4% lidocaine and insert 
slowly until terminal depth is achieved. Mark depth level of each swab and re-check 
depth frequently as patient talking and swallowing will displace swab and require 
slight advancement.  
c. Once the initial lidocaine-soaked swab is inserted and maximal depth is achieved, 
remove the swab and replace it with a new clean soaked swab (this removes the 
mucous coating that often accumulates on the initial swab during insertion. Fill the 
hollow tube with 4% lidocaine and allow to soak with patient in supine position. 
d. Every 10 min, gently rotate each swab 180 degrees and assure hollow swab tube is 
full and swab remains in contact with sphenopalatine and assess for relief. 
e. It often takes at least 20 minutes and can take as long as 60 minutes for relief. 
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Literature-based Evidence and Strength of Evidence / Grading 
Authors / 
Article 
Study Design & 
Methods  
Research 
Question or 
Hypothesis 
Sample (n) 
& Setting 
Variables, data 
types, and results 
Strength of Evidence 
Cady, R., Saper, J.,  
 Dexter, K.,  
 & Manley, H. (2014).  
 A double-blind,  
 placebo-controlled  
 study of repetitive  
 transnasal  
 sphenopalatine  
 ganglion blockade  
 with Tx360® as an  
 acute treatment for a  
 chronic migraine  
 Headache: The  
 Journal of Head and  
 Face Pain, 55(1),  
 101-116. 
 
RCT, double-blinded 
study 
0.3 ml of 0.5% 
bupivacaine using Tx 
360 device 
Repetitive SPGNBs 
using the Tx360 
devise with a series 
of 12 SPGNBs 
provided 2 times per 
week for 6 weeks. 
SPGNB using Tx360 
device vs. normal 
saline placebo for 
treatment of chronic 
migraine headaches 
n=38 
Control n= 12 
SPGNB n = 26 
Randomly 
assigned patients 
from two US 
specialty 
headache clinics 
Treatment group 
experienced a significant 
reduction in headaches vs 
control group at 15 and 30 
minutes (M=3.78 vs M-
3.18, P=.10) and (M=3.51 
vs M = 2.53, P<.001). 
From pre-treatment to final 
treatment (following 6-
week period) the treatment 
group experienced a 
statistically significant 
reduction in headache pain 
vs. control (M diff = -4.52, 
P=.005) vs. (M dif = -1.5, 
P = .13). 
2B – Recommended 
 
Clinicians should generally 
follow a recommendation but 
should remain alert to new 
information and remain 
sensitive to patient preferences 
 
Cardoso, J., Sá, M.,  
 Graça, R.,  
 Reis, H., Almeida, L.,  
 Pinheiro, C., &  
 Machado, D. (2017).  
 Sphenopalatine  
 ganglion block for  
 postdural puncture  
 headache in  
 ambulatory  
 setting. Brazilian  
 Journal  
 of Anesthesiology  
 (English  
 Edition), 67(3), 311- 
 313.  
Case Report  
Cotton-tipped 
applicator saturated 
with 0.5% 
levobupivacaine for 5 
minutes. 
 
SPGNB versus prior 
trial with crystalloid, 
dexamethasone, 
parecoxib, Tylenol 
and caffeine. 
n=1 
41-year-old 
female 
s/p PDPH for 1 
week 
The ambulatory 
setting in Brazil 
The patient reported 0/10 
pain after 5 minutes of 
SPGNB. Remained pain-
free at 1 day and 7 days 
post-procedure, did have 
OTC pain medication to 
take at home PRN 
5D – Option 
 
Clinicians should consider all 
options in their decision 
making and be alert to new 
published evidence that 
clarifies the balance of benefit 
versus harm; patient preference 
should have a substantial 
influencing role 
Channabasappa, S.,  
 Manjunath, S.,  
 Bommalingappa, B.,  
 Ramachandra, S., &  
 Banuprakash, S.  
 (2017).  
 Transnasal  
 sphenopalatine  
 ganglion block for the  
 treatment of postdural  
 puncture headache  
 following spinal  
 anesthesia. Saudi  
 Journal of  
 Anaesthesia, 11(3),  
 362. 
Case Study 
5 ml of a pre-loaded 
syringe with 0.5% 
ropivacaine attached 
to a cotton-tipped 23-
g spinal needle. 
SPGNB was 
accomplished with 
injection vs. topical 
saturation of local 
anesthetic on ganglia. 
Will SPGNB prevent 
the need for epidural 
blood patch in PDPH 
parturient? 
n=1 
PDPH following 
combined spinal-
epidural for C-
section in 
hospital in India 
 
Instantaneous and 
sustained pain relief. 24 
hours post-procedure, the 
patient remained pain-free 
and follow-up at 3 weeks 
post-procedure revealed 
continued pain-free scores. 
5D – Option 
 
Clinicians should consider all 
options in their decision 
making and be alert to new 
published evidence that 
clarifies the balance of benefit 
versus harm; patient preference 
should have a substantial 
influencing role 
Cohen, S., Sakr, A.,  
 Katyal, S.,  
 & Chopra, D. (2009).  
 Sphenopalatine  
 ganglion block for  
 postdural puncture  
 headache.  
 Anaesthesia, 64(5),  
 574-575 
Case Series 
Cotton-tipped 
applicator soaked 
with 4% lidocaine 
ointment 
SPGNB effectiveness 
on 1st vs. subsequent 
blocks 
n=13 
Unknown setting 
11 of the 13 patients 
received immediate and/or 
complete relief following 
1st SPGNB (84.6% 
reported success) 
4C – Option 
 
Clinicians should be flexible in 
their decision-making regarding 
appropriate practice, although 
they may set bounds on 
alternatives; patient preference 
should have a substantial 
influencing role 
Cohen, S., Ramos, D.,  
 Grubb, W.,  
 Mellender, S.,  
 Mohiuddin, A., &  
 Chiricolo,  
 A. (2014).  
 Sphenopalatine  
 Ganglion Block.  
 Regional Anesthesia  
 and Pain Medicine,  
 39(6), 563. 
 
 
Case Series 
Cotton-tipped 
applicator saturated 
with 5% water-
soluble lidocaine 
ointment left in place 
for 10 minutes 
SPGNB effectiveness 
for treatment of 
PDPH amongst 
obstetric patients, 
eliminating the need 
for epidural blood 
patch 
n=32 
Obstetrical 
patients suffering 
from PDPH 
following 
accidental dural 
puncture from a 
17-gauge 
epidural needle 
69% reported success in 
relieving PDPH by use of 
SPGNB amongst 32 
obstetric patients, 
eliminating the need for an 
epidural blood patch 
4C – Option 
 
Clinicians should be flexible in 
their decision-making regarding 
appropriate practice, although  
they may set bounds on 
alternatives; patient preference 
should have a substantial 
influencing role 
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Cohen, S., Trnovski, S.,  
 & Zada, Y. (2001). A  
 new interest in an old  
 remedy for a headache  
 and backache for our  
 obstetric patients: a  
 sphenopalatine  
 ganglion block.  
 Anesthesia,  
 56(6), 606-607. 
 
Case Report 
Cotton-tipped 
applicator saturated 
with EMLA cream 
for 10 minutes 
(2 of the 22 patients 
could not tolerate the 
EMLA cream and so 
they were given 
Cetacaine nasal spray 
instead) 
SPGNB for treatment 
of moderate to a 
severe backache or a 
headache amongst 
obstetrical patients 
n=22 
Obstetrical 
patients 
Complaining of 
moderate to a 
severe backache 
and headache 
during a hospital 
stay 
100% of patients 
experienced complete 
relief of pain within 6-10 
minutes of SPGNB 
procedure. 
No side-effects reported 
amongst any of the n=22 
participants. 
5D – Option 
 
Clinicians should consider all 
options in their decision 
making and be alert to new 
published evidence that 
clarifies the balance of benefit 
versus harm; patient preference 
should have a substantial 
influencing role 
Furtado, I., Lima, I., &  
 Pedro, S. (2017).  
 Ropivacaine use in  
 Transnasal 
 Sphenopalatine  
 ganglion block for  
 post dural a puncture  
 headache in obstetric  
 patients – case series.  
 Brazilian Journal of  
 Anesthesiology  
 (English Edition). 
 
 
 
Case Series 
4 ml of 0.75% 
ropivacaine 
Applicator left in 
place for 15-20 
minutes 
 
SPGNB effectiveness 
in obstetrical patients 
suffering from 
PDPH. Will the 
application of 
SPGNB prevent the 
need for epidural 
blood patch? 
N=4 
Labor and 
Delivery, OB 
patients in 
Portugal 
Case 1. No relief from 
conservative treatment x 
24 hrs. SPGNB provided 
100% relief without 
remission following 7 days 
Case 2. PDPH pain went 
from 6-8/10 immediately 
to 0/10 following SPGNB. 
The pain returned to 4/10 
and required 2nd SPGNB 
with 100% relief and no 
remission 
Case3. The patient 
reported PDPH pain of 4-
6/10 with 100% relief 
following SPGNB, 
however, patient required 
epidural blood patch which 
failed to resolve PDPH. 
Ultimately patient was 
discharged home with 3/10 
pain 
Case 4. PDPH pain score 
of 7/10 was immediately 
relieved to 0/10 following 
SPGNB. The patient 
remained pain-free for48 
hrs, the however pain 
returned and epidural 
blood patch was 
performed. 
4C – Option 
 
Clinicians should be flexible in 
their decision-making regarding 
appropriate practice, although 
they may set bounds on 
alternatives; patient preference 
should have a substantial 
influencing role 
 
Kent, S., & Mehaffey, G.  
 (2015). Transnasal  
 sphenopalatine  
 ganglion  
 block for the  
 treatment of  
 postdural puncture  
 headache in the ED.  
 The American  
 Journal of  
 Emergency Medicine,  
 33(11), 1714.e1-  
 1714.e2. 
Case Report 
2% viscous lidocaine 
on long, cotton-
tipped applicators, 
left in place for 10 
minutes, re-applied 
for additional 20 
minutes. 
SPGNB effectiveness 
for PDPH following 
diagnostic lumbar 
punctures 
n=3 
Emergency 
department. 
PDPH following 
diagnostic lumbar 
punctures using 
spinal needles 
Patient 1. An initial 
headache 8/10 went to 1/10 
with no further treatment 
needed 
Patient 2. An initial 
headache 9/10 was reduced 
to 4/10 following SPGNB, 
however patient later 
sought out epidural blood 
patch at another facility 
Patient 3. An initial 
headache 9/10 with 
SPGNB relief of 1/10 
5D – Option 
 
Clinicians should consider all 
options in their decision 
making and be alert to new 
published evidence that 
clarifies the balance of benefit 
versus harm; patient preference 
should have a substantial 
influencing role  
Kent, S., & Mehaffey, G.  
 (2016). Transnasal  
 sphenopalatine  
 ganglion  
 block for the  
 treatment of  
 postdural puncture  
 headache in obstetric  
 of Clinical Anesthesia,  
 34, 194-196. 
 
Case Report 
2% viscous lidocaine 
on long, cotton-
tipped applicators, 
left in place for 10 
min, then additional 
2% lidocaine 
reapplied and 
applicator re-inserted 
for additional 20 min. 
SPGNB effectiveness 
in obstetric patients 
suffering from 
PDPH. Will the 
SPGNB avoid the 
need for epidural 
blood patch? 
n=3 
Labor and 
Delivery Suite. 
Post-partum 
obstetrical 
patients suffering 
from PDPH 
All 3 patients had 
“significant” relief from 
PDPH following SPGNB 
and all three avoided the 
need for epidural blood 
patch. 
An initial headache vs. 
post-SPGNB headache 
scores as follows: 
Patient 1. 9/10 to 0/10 
Patient 2. 8/10 to 0/10 
Patient 3. 9/10 to 0/10 
5D – Option 
 
Clinicians should consider all 
options in their decision 
making and be alert to new 
published evidence that 
clarifies the balance of benefit 
versus harm; patient preference 
should have a substantial 
influencing role 
Patel, P., Zhao, R.,  
 Cohen, S.,  
 Mellender, S., Shah,  
 S., & Grubb, W.  
 (2016).  
 Sphenopalatine  
 ganglion  
 block (SPGB) versus  
Retrospective 
observational study 
over a 17-year period 
(Abstract Only) 
Epidural blood patch 
vs SPGNB for PDPH  
n=72 
n=33 SPGNB 
n=39 = epidural 
blood patch 
Parturients with 
no previous 
history of 
primary headache 
Retrospective data analysis 
of 72 records spanning 17 
years. No differences in 
ASA scores, patient age, 
height, weight or BMI 
At 24 hours post-treatment, 
no difference in pain 
scores amongst SPGNB 
3C – Option 
 
Clinicians should be flexible in 
their decision-making regarding 
appropriate practice, although 
they may set bounds on 
alternatives; patient preference 
should have a substantial 
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Level Type of evidence
1A Systematic review (with homogeneity) of RCTs
1B Individual RCT (with narrow confidence interval)
1C All or none study
2A Systematic review (with homogeneity) of cohort studies
2B Individual cohort study (including low quality RCT)
2C "Outcomes" research; Echological studies
3A Systematic review (withhomogeneity) of case-control studies
3B Individual case-control studies
4 Case series (and poor quality cohort and case-control studies)
5 Expert opinion; case report or clinical example; or evidence based on physiology
Burns, P., Rochrich, R., Chung, K. (2011). The levels of evidence and their role in 
evidence-based medicine.  Plastic and Reconstructive Surgery, 128(1), 305-310.
Reprinted with permission.
Grade Descriptor Qualifying Implications for Practice
Evidence
A Strong Level 1 evidence or Clinicians should follow strong
recommendation consistent findings recommendations unless clear or compelling
from multiple rationale for an alternative approach is present
studies of levels II, 
III, or IV
B Recommendation Levels II, III, or IV Generally, clinicians should follow a
evidence and recommendation but should remain alert to new
findings are information and sensitive to patient preferences
generally consistent
C Option Levels II, III, or IV Clinicians should be flexible in their decision-
evidence, but making regarding appropriate practice, although
findings are they may set bounds on alternatives; patient
inconsistent preference should have a substantial influencing
role
D Option Level V evidence; Clinicians should consider all options in their
little or no decision making and be alert to new published
systematic empirical evidence that clarifies the balance of benefit 
evidence versus harm; patient preference should have a
substantial influencing role
Burns, P., Rochrich, R., Chung, K. (2011). The levels of evidence and their role in evidence-based medicine.  
Plastic and Reconstructive Surgery, 128(1), 305-310. Reprinted with permission.
 epidural blood patch 
 for accidental  
 postdural  
 puncture headache  
 (PDPH) in obstetric  
 patients: A  
 retrospective  
 The American  
 Academy of  
 Pain Medicine,  
 Abstract 145, 1. 
 
 
 
 
 
 
 
 
 
disorders who 
were 
experiencing 
PDPH 
and epidural blood patch 
group 
SPGNB group experienced 
improved headache scores 
at 30 min post procedure 
vs epidural blood patch 
(54.55% relief vs. 20.51%) 
and at 60 minutes post 
procedure, SGNB group 
had 63.64% relief vs. 
30.77% for epidural blood 
patch group. 
SPNB group had no 
complications, vs epidural 
blood patch group had 9 
patients return to ED for 
complications, including 
radiating back pain, 
vasovagal reaction or 
hearing loss. 
influencing role 
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Randomized, 
Placebo-Controlled 
Trial  
Tx360 devise for 
application of 
SPGNB using 0.3 ml 
of 0.5% bupivacaine 
delivered by the  
Tx 360 device.  
 
SPGNB vs. placebo 
treatment for Acute 
Headache in ED. 
The hypothesis was 
that the Tx360 
SPGNB devise would 
achieve a 50% 
reduction in anterior 
headache pain vs. 
saline placebo 
delivered using same 
technique at the 15-
minute post-
procedure mark. 
n=93 
Control n = 48 
SPGNB n = 45 
2 large academic 
emergency 
departments of 
Level 1 facilities 
between Oct 
2012 to Oct 2013 
The treatment group n=45, 
did not experience a 
statistically significant 
improvement (risk 
difference of 7.5% with 
95% CI) at the 15-minute 
mark and 
secondary outcomes 
revealed similar nausea 
scores at 15 minutes post-
procedure (risk difference 
of 3.5% with 95% CI of 
15.3% vs. 21.8%).  
Post 24-hour follow-up 
revealed treatment group 
was a headache free (with 
a statistical significance) 
with 72.2% vs. 47.5% for 
the control group. 
 
2C – Option 
 
Clinicians should be flexible in 
their decision-making regarding 
appropriate practice, although 
they may set bounds on 
alternatives; patient preference 
should have a substantial 
influencing role 
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Modified NYSORA Algorithm 
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Methods 
 
Search Methods and Criteria Selection 
 
Commonly accepted scientific literature search engines were used to find relevant literature 
supporting the inclusion of SPG blocks for PDPH. CINAHL, Ovid, PubMed, Google Scholar 
and clinicaltrials.gov were searched using keywords and phrases, including "sphenopalatine 
ganglion" OR "SPG" OR "pterygopalatine ganglion" OR "Meckel's ganglion" AND "postdural 
puncture" OR "postdural puncture" OR "a headache". Additionally, a search was conducted 
using "clinical practice guidelines" OR "CPG" OR "treatment recommendations" OR "treatment 
guidelines" AND "postdural puncture headache" OR “postdural puncture headache” OR 
“PDPH”. Only original research studies, abstracts, and reports were selected, eliminating all 
other duplicate or editorial articles that were not directly reporting original study data or 
observations.  
 
AGREE II CPG Scoring Assessment 
 
 
This CPG was scored by two anesthesia providers practicing at MVMC using the 
AGREE II CPG assessment tool. Six domains were evaluated, including Scope and Purpose, 
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Stakeholder Involvement, Rigour of Development, Clarity of Presentation, Applicability, 
Editorial Independence and Overall Guideline Assessment. In the two graphics above, both the 
original, unmodified NYSORA CPG (left graphic) and the post-modification CPG were graded 
using the AGREE II tool and scores can be compared between the pre and post CPG 
modification. Across all six domains and all 23 individuals, the post-modification scores have 
increased significantly, providing stakeholders at MVMC an improved and locally adapted CPG 
for the treatment of PDPH. The overall CPG score improved from 55% to 80% and four out of 
the six domains achieved the 70% quality threshold mark which was determined to be threshold 
as a quality domain. The graph below depicts a graphical representation of each of the six 
domains reflecting the improvement across each of these measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Updating Procedure 
 
 To reflect current and emerging literature and research, the recommendations contained 
within this modified CPG will undergo periodic (every 3 to 5 year) review by key stakeholders at 
MVMC with input, as requested, from additional outside peers and experts. 
 
Stakeholder Involvement 
 
Stakeholders from Anesthesia Physicians of Arizona practicing at MVMC have 
participated in this CPG modification. Involvement included expert consultation and input on the 
CPG modification and grading of the CPG using the ARGEE II tool. This effort has been the 
product of a Doctor of Nursing Practice project, authored by Gregg Tidrick, SRNA from the 
University of Arizona College of Nursing / Anesthesia Specialty Program. Local participating 
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stakeholders from MVMC included Ned Sciortino MD, Craig Ryan, chief CRNA, Aaron 
Whitley, DNP, CRNA, Chad Boesl, CRNA and Ryan Wight, CRNA.  
 
Facilitators/Barriers to Implementation 
 
This CPG modification has been developed for implementation at Mountain Vista 
Medical Center. Stakeholders from the site have provided input and expert opinion aiding in the 
modification process improving the applicability for anesthesia providers practicing at MVMC. 
As part of this input and consideration, barriers and limitations to implementation have been 
considered, as have potential financial and familiarization of technique concerns. 
 
Funding/Conflict of Interest 
 
 The modification of the NYSORA CPG for application at MVMC is part of an educational 
Doctor of Nursing Practice project and as such, there are no conflicts of interest or financial 
conflicts to disclose. The project was completed free of funding requirements and all participants 
did so on a volunteer basis. 
 
Disclaimer 
 
 The information and recommendations presented in this CPG modification represent 
current literature and expert concensus opinion. As an anesthesia professional considering any of 
these recommendations or relying on data presented in this CPG modification are reminded to 
use professional independent judgement, consult reliable resources and, where appropriate, seek 
additional expert consultation. 
 
REFERENCES 
 
Burns, P., Rohrich, R., & Chung, K. (2011). The levels of evidence and their role in evidence-  
based medicine. Plastic and Reconstructive Surgery, 128(1), 305-310. 
 
Cady, R., Saper, J., Dexter, K., & Manley, H. (2014). A double-blind, placebo-controlled  
study of repetitive transnasal sphenopalatine ganglion blockade with Tx360® as an acute 
treatment for chronic migraine. Headache: The Journal of Head and Face Pain, 55(1), 
101-116. 
 
Cardoso, J., Sá, M., Graça, R., Reis, H., Almeida, L., Pinheiro, C., & Machado, D. (2017).  
Sphenopalatine ganglion block for postdural puncture headache in ambulatory setting. 
Brazilian Journal of Anesthesiology (English Edition), 67(3), 311-313. 
 
Channabasappa, S., Manjunath, S., Bommalingappa, B., Ramachandra, S., & Banuprakash, S. 
(2017). Transnasal sphenopalatine ganglion block for the treatment of postdural puncture 
headache following spinal anesthesia. Saudi Journal of Anaesthesia, 11(3), 362. 
 
   
59 
Cohen, S., Trnovski, S., & Zada, Y. (2001). A new interest in an old remedy for headache and  
backache for our obstetric patients: A sphenopalatine ganglion block. Anaesthesia, 56(6),  
606-607. 
 
Cohen, S., Ramos, D., Grubb, W., Mellender, S., Mohiuddin, A., & Chiricolo, A. (2014).  
Sphenopalatine ganglion block. Regional Anesthesia and Pain Medicine, 39(6), 563.  
 
Cohen, S., Sakr, A., Katyal, S., & Chopra, D. (2009). Sphenopalatine ganglion block for  
postdural puncture headache. Anaesthesia, 64(5), 574-
575.http://dx.doi.org/10.1111/j.1365-2044.2009.05925.x 
 
Furtado, I., Lima, I., & Pedro, S. (2017). Ropivacaine use in transnasal Sphenopalatine  
ganglion block for post dural puncture headache in obstetric patients – case series. 
Brazilian Journal of Anesthesiology (English Edition). 
 
Kent, S., & Mehaffey, G. (2015). Transnasal sphenopalatine ganglion block for the treatment of  
postdural puncture headache in the ED. The American Journal of Emergency Medicine, 
33(11), 1714.e1-1714.e2. 
 
Kent, S., & Mehaffey, G. (2016). Trans-nasal sphenopalatine ganglion block for the treatment of  
postdural puncture headache in obstetric patients. Journal of Clinical Anesthesia, 34, 
194-196.  
 
Patel, P., Zhao, R., Cohen, S., Mellender, S., Shah, S., & Grubb, W. (2016). Sphenopalatine  
ganglion block (SPGB) versus epidural blood patch for accidental postdural puncture 
headache (PDPH) in obstetric patients: A retrospective observation. The American 
Academy of Pain Medicine, Abstract 145, 1. 
 
Rigdon, S (2017). Sphenopalatine Ganglion Block: Clinical Use and Placement [PowerPoint  
presentation]. Retrieved from http://ce2you.com/events/phoenix-usgra-and-vascular-
access-workshop/ 
 
Schaffer, J., Hunter, B., Ball, K., & Weaver, C. (2015). Noninvasive sphenopalatine ganglion  
 block for acute headache in the emergency department: A randomized placebo-controlled 
 trial. Annals of Emergency Medicine, 65(5), 03-510. 
 
 
   
60 
APPENDIX C: 
AGREE II SCORE SHEET 
 
   
61 
 
   
62 
APPENDIX D: 
PRE- AND POST-CPG MODIFICATION AGREE II SCORES 
 
   
63 
PRE- AND POST-CPG MODIFICATION AGREE II SCORES 
 
This CPG was scored by two anesthesia providers practicing at the local facility using the 
AGREE II CPG assessment tool. Six domains were evaluated, including Scope and Purpose, 
Stakeholder Involvement, Rigour of Development, Clarity of Presentation, Applicability, 
Editorial Independence and Overall Guideline Assessment. In the two graphics above, both the 
original, unmodified NYSORA CPG (left graphic) and the post-modification CPG were graded 
using the AGREE II tool and scores can be compared between the pre- and post-CPG 
modification. Across all six domains and all twenty-three individuals, the post-modification 
scores have increased significantly, providing stakeholders at the local facility an improved and 
locally adapted CPG for the treatment of PDPH. The overall CPG score improved from 55% to 
80% and four out of the six domains achieved the 70% quality threshold mark which was 
determined to be threshold as a quality domain.  
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1618 E. Helen St.
P.O.Box 245137
Tucson, AZ 85724-5137
Tel: (520) 626-6721
http://rgw.arizona.edu/compliance/home
Human Subjects
Protection Program
 
Date: September 13, 2018
Principal Investigator:  Gregg Alan Tidrick
Protocol Number: 1809921971
Protocol Title: MODIFICATION OF A CLINICAL PRACTICE GUIDELINE FOR
THE TREATMENT OF POST-DURAL PUNCTURE HEADACHES
TO INCLUDE SPHENOPALATINE GANGLION NERVE BLOCK
Determination: Human Subjects Review not Required
Documents Reviewed Concurrently:
     Data Collection Tools:  AGREE II SCORE SHEET.DOCX
     Data Collection Tools:  Practicioner Feedback Questionnaire.docx
     HSPP Forms/Correspondence:  Advisor Confirmation Email.pdf
     HSPP Forms/Correspondence:  Determination of Human Research_Tidrick_v3.pdf
     Other:  AGREE II Appraiser Training Confirmation.docx
     Other:  Clinical Practice Guideline.docx
     Other Approvals and Authorizations:  Site Authorization Letter.docx
     Recruitment Material:  E-mail- AGREE Assessment Template.doc
     Recruitment Material:  E-mail- Expert Consultation Template.doc
Regulatory Determinations/Comments:  
• Not Human Subjects Research as defined by 45 CFR 46.102(f): as presented, the activities
described above do not meet the definition of research involving human subjects as cited
in the regulations issued by the U.S. Department of Health and Human Services which
state that "human subject means a living individual about whom an investigator (whether
professional or student) conducting research obtains data through intervention or interaction
with the individual, or identifiable private information."
The project listed above does not require oversight by the University of Arizona.
If the nature of the project changes, submit a new determination form to the Human Subjects
Protection Program (HSPP) for reassessment. Changes include addition of research with children,
specimen collection, participant observation, prospective collection of data when the study was
previously retrospective in nature, and broadening the scope or nature of the study activity.  Please
contact the HSPP to consult on whether the proposed changes need further review.
The University of Arizona maintains a Federalwide Assurance with the Office for Human
Research Protections (FWA #00004218) .
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